Roberta Faccio

7PUBLICATIONS

36CO-AUTHORS

Predictive and prognostic markersMedical infection agents (incl. prions)Molecular targetsAutoimmunityMetabolic medicine

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (7)

Sort by Publication Date:

|Jun 11, 2026

Bone-derived Osterix+ osteolineage cells are a source of tumor-promoting myofibroblastic cancer-associated fibroblasts in breast cancer.

|Apr 21, 2026

Activation of the NLRP3 inflammasome in osteoclasts is suppressed by a Tmem178-dependent mechanism that restricts Ca<sup>2+</sup> influx.

|Nov 24, 2025

Myofibroblastic CAFs arising from bone-resident osteoblast precursors retain an osteolineage signature and support breast cancer progression via Osterix-mediated signaling.

Giulia Furesi, Carisa Zeng, Emily M Eul

|Jan 30, 2025

Stroma-derived Dickkopf-1 contributes to the suppression of NK cell cytotoxicity in breast cancer.

Seunghyun Lee, Biancamaria Ricci, Jennifer Tran

|Aug 03, 2023

Tmem178 Negatively Regulates IL-1β Production Through Inhibition of the NLRP3 Inflammasome.

Kunjan Khanna, Hui Yan, Muneshwar Mehra

|Aug 07, 2020

Osterix-Cre marks distinct subsets of CD45- and CD45+ stromal populations in extra-skeletal tumors with pro-tumorigenic characteristics.

Biancamaria Ricci, Eric Tycksen, Hamza Celik

Pageof 2

Frequent Collaborators

Deborah J Veis

Hui Yan

Maxim N Artyomov

Gabriel Mbalaviele

Marco Colonna

Sheila A Stewart

Allahdad Zarei

Gregory D Longmore

Biancamaria Ricci

Seunghyun Lee

Frequent Collaborators

Deborah J Veis

Hui Yan

Maxim N Artyomov

Gabriel Mbalaviele